Finally, EGFR signaling seems to be an essential in vivo requirement in HH-driven BCC because EGFR signaling cooperates with the HH pathway to induce genes (e.g., JUN, SOX9, and FGF19) critical for the determination of the oncogenic BCC phenotype [22]. This evidence concerns the gene SOX9 and skin basal cell carcinoma.